{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:00:03Z","timestamp":1773806403049,"version":"3.50.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Fatigue is one of the most common adverse events of systemic therapy in patients with metastatic renal cell carcinoma (RCC). The aim of multicenter randomized phase 2 study was to determine the efficacy and safety of testosterone in patients with fatigue developed during targeted therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>Male patients with metastatic clear-cell RCC, normal prostate-specific antigen level, low testosterone level, and no evidence of hypothyroidism receiving first-line sunitinib or pazopanib with fatigue were randomly assigned (1:1) to either testosterone undecanoate (1000\u2009mg) and targeted therapy or targeted therapy alone. The primary endpoint was the mean change of fatigue from baseline to 28 days according to the Functional Assessment of Chronic Illness Therapy\u2014Fatigue scale. Secondary endpoints were safety, Functional Assessment of Cancer Therapy\u2014Kidney Symptom Index 19, testosterone serum concentrations, red blood cell count, and hemoglobin level.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Sixty patients were assigned to receive testosterone and targeted therapy (N=30) or targeted therapy alone (N=30). As of the data cutoff on December 30, 2019, median follow-up was 18.2 months. The study achieved its primary endpoint based on the significant differences at day 28 favoring testosterone over targeted therapy alone regarding the decreased level of fatigue (difference between groups, 22.5 points; 95% confidence interval, 18.4-26.6; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.012). Significant changes in scores demonstrating the enhanced quality of life with testosterone compared with targeted therapy were also observed for Functional Assessment of Cancer Therapy\u2014Kidney Symptom Index 19 disease-related symptoms (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.01). There were nonsignificant differences in red blood cell count and hemoglobin level between the 2 groups (all <jats:italic toggle=\"yes\">P<\/jats:italic>&gt;0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Male patients with metastatic RCC and hypogonadism receiving testosterone had less fatigue and better symptom control during targeted therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000797","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T05:17:03Z","timestamp":1611897423000},"page":"137-142","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma"],"prefix":"10.1097","volume":"44","author":[{"given":"Ilya","family":"Tsimafeyeu","sequence":"first","affiliation":[{"name":"Kidney Cancer Research Bureau"},{"name":"Institute of Oncology, Hadassah Medical Moscow"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Tishova","sequence":"additional","affiliation":[{"name":"RUDN University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruslan","family":"Zukov","sequence":"additional","affiliation":[{"name":"V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Borisov","sequence":"additional","affiliation":[{"name":"City Clinical Oncology Center, St. Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Bondarenko","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Zakurdaeva","sequence":"additional","affiliation":[{"name":"RakFond, Moscow"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11523-018-0613-y","article-title":"Phase 2 multicenter single-arm study of second-line axitinib in favorable risk patients with metastatic renal cell carcinoma: FavorAx","volume":"14","author":"Tsimafeyeu","year":"2019","journal-title":"Target Oncol"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.mayocp.2019.03.012","article-title":"Immune checkpoint inhibitor toxicities","volume":"94","author":"Marin-Acevedo","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"R8-20250527","first-page":"43","article-title":"Mechanisms underlying the inhibition of tyrosine kinase inhibitor-induced anorexia and fatigue by Royal Jelly in renal cell carcinoma patients and the correlation between macrophage colony stimulating factor and inflammatory mediators","volume":"8","author":"Yuno","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cas.14294","article-title":"Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101","volume":"111","author":"Uemura","year":"2020","journal-title":"Cancer Sci"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"e1069","DOI":"10.1016\/j.clgc.2017.07.017","article-title":"Five-year survival of patients with metastatic renal cell carcinoma in the Russian Federation: results from the RENSUR5 Registry","volume":"15","author":"Tsimafeyeu","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/17843286.2018.1476115","article-title":"Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies","volume":"74","author":"Bastin","year":"2019","journal-title":"Acta Clin Belg"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13539-012-0065-7","article-title":"Hypogonadism in male cancer patients","volume":"3","author":"Burney","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jpainsymman.2009.09.021","article-title":"Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report","volume":"39","author":"Del Fabbro","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"403.e2","DOI":"10.1016\/j.clgc.2017.01.005","article-title":"Discontinuing VEGF-targeted therapy for progression versus toxicity affects outcomes of second-line therapies in metastatic renal cell carcinoma","volume":"15","author":"De Velasco","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdq437","article-title":"Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy","volume":"22","author":"Johannsen","year":"2011","journal-title":"Ann Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:08:31Z","timestamp":1748365711000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000797"}},"subtitle":["A Phase 2 Randomized Study FARETES"],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000797","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,27]]}}}